Other Financings Of Public Biotechnology Companies: February 2008 |
| Total: $578.325M |
| Company (Symbol)# | Type Of Financing | Number Of Shares, Units Or Warrants (M) | Amount Raised (M) | Investors; Placement Agents; Details (Date)@ |
| Bioniche Life Sciences Inc. (Canada; TSX:BNC) | Commercial loan | N/A | $5 | Bioniche secured a $5M loan from the Business Development Bank of Canada (2/8) |
| Cadence Pharmaceuticals Inc. (CADX) | Registered direct common stock offering | 9.24S | $49.3 | Cadence received commitments to purchase up to 9.24M shares at $5.34 (2/18) |
| Chemokine Therapeutics Corp. (Canada; OTC BB:CHKT) | Private placement of units | 5.25U | $1.05 | Chemokine raised $1.05M through the placement of 5.25M units, each consisting of one share of common stock at an exercise price of 30 cents per share (2/8) |
| Cytori Therapeutics Inc. (CYTX) | Equity investment | 2S | $12 | Cytori raised $12M under an agreement with its stem cell marketing partner, Green Hospital Supply Inc., which purchased 2M shares of unregistered Cytori common stock at $6 per share (2/8) |
| DOR BioPharma Inc. (OTC BB: DORB) | Private placement of common stock and a warrant | 2.8S and W for 1.4S | $0.5 | DOR signed an $8.5M common stock purchase agreement with Fusion Capital Fund II LLC; Fusion bought 2.8M shares and a warrant for 1.4M shares at 22 cents per share for $500,000, and DOR has the right to sell shares to bring in up to $8M more from time to time (2/14) |
| Echo Therapeutics Inc. (OTC BB: ECTE) | Private placement of senior convertible notes and warrants | Notes and W for 0.85S | $2.3 | Echo completed a $2.3M financing with Montaur Capital through Platinum Long Term Growth VII LLC and other investors of senior unsecured convertible notes and warrants (2/13) |
| Genta Inc. (GNTA) | Private placement of common stock | 6S | $3.1 | Genta raised $3.1M selling 6M shares; Rodman & Renshaw LLC served as the placement agent (2/11) |
| Helix BioMedix Inc. (OTC BB:HXBM) | Private placement of a convertible note and warrant | N/A | $3 | Helix raised $3M in the placement (2/25) |
| Icagen Inc. (ICGN) | Private placement of common stock | N/A | $10 | Icagen has exercised its put option under an August 2007 deal with Pfizer for the private placement of 5.8M shares at $1.71 each (2/6) |
| Insite Vision Inc. (AMEX:ISV) | Private placement of nonconvertible, nonrecourse promissory notes | N/A | $60 | Insite raised $60M through the placement (2/25) |
| Isis Pharmaceuticals Inc. (ISIS) | Equity investment | 5S | $150 | Genzyme Corp. is paying Isis $150M for 5M shares at $30 a share as part of a collaboration to license mipomersen (2/1) |
| GTC Biotherapeutics Inc. (GTCB) | Private placement of common stock | 6.9S | $6 | GTC raised $6M through a placement of 6.9M shares at 87 cents per share (2/8) |
| Medarex Inc. (MEDX) | Stock sale | 2.5S | $151.8 | Medarex raised $151.8M selling 2.5M shares of Genmab AS, reducing its ownership in the Danish firm from about 11% to 5.1% (2/1) |
|
OccuLogix Inc. (OCCX) |
Bridge loan | N/A | $3 | OccuLogix secured a $3M bridge loan (2/20) |
| Oragenics Inc. (AMEX:ONI) | Exercise of warrants | 1.1W | $0.5 | Oragenics gained $500,000 due to seven share-holders exercising warrants as part of their March 2006 investment in the company (2/13) |
| OxiGene Inc. (OXGN) | Committed Equity Financing Facility | N/A | $40 | OxiGene secured a three-year, $40M CEFF through Kingsbridge Capital Ltd. (2/20) |
|
Pharmexa A/S (Denmark; CSE:PHARMX) |
Rights issue | 18.2S | DKK91.2 ($18) |
Pharmexa raised $18M in a rights issue of 18.2M shares at DKK5 per share (2/6**) |
| Pro-Pharmaceuticals Inc. (AMEX:PRW) | Registered direct offering | 7.55S | $3.775 | Pro-Pharmaceuticals entered into agreements with new and existing investors to raise $3.775M through an offering of 7.55M shares at 50 cents per share (2/18) |
| RegeneRx Bio-pharmaceuticals Inc. (AMEX:RGN) | Private placement of common stock | 5S | $5 | RegenRx raised $5M selling 5M shares at $1 each; it also agreed to issue warrants to purchase an additional 1M shares with an exercise price of $1.60 per share (2/27) |
| Verenium Corp. (VRNM) | Securities purchase agreement | N/A | $54 | Verenium entered the agreement with institutional investors to raise about $54M (2/25) |
|
Notes: This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. Funds from loan facilities are included only when the company takes a draw, if announced. # Unless otherwise indicated, shares are traded on the Nasdaq exchange@ Refers to the date of the press release. ** Denotes the date the item ran in BioWorld International.Currency conversions are based on exchange rates at the time of the deal. N/A = Not applicable. AMEX = American Stock Exchange; CSE = Copenhagen Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange. | ||||